Treatment for opioid use disorder in the Florida medicaid population: Using a cascade of care model to evaluate quality

References

• Rudd RA. Increases in drug and opioid-involved overdose deaths—United States, 2010–2015. MMWR Morb Mortal Wkly Rep. 2016;65:1445–52. doi:10.15585/mmwr.mm655051e1.
   PubMed Web of Science ®Google Scholar
• O’Donnell JK, Gladden RM, Seth P. Trends in deaths involving heroin and synthetic opioids excluding methadone, and law enforcement drug product reports, by census region—United States, 2006–2015. MMWR Morb Mortal Wkly Rep. 2017;66:897. doi:10.15585/mmwr.mm6634a2.
   PubMed Web of Science ®Google Scholar
• Scholl L, Seth P, Kariisa M, Wilson N, Baldwin G. Drug and opioid-involved overdose deaths—United States, 2013–2017. MMWR Surveill Summ. 2019;67:1419.
   Google Scholar
• Jones CM, Campopiano M, Baldwin G, McCance-Katz E. National and state treatment need and capacity for opioid agonist medication-assisted treatment. Am J Public Health. 2015;105:e55–e63. doi:10.2105/AJPH.2015.302664.
   PubMed Web of Science ®Google Scholar
• Haffajee RL, Bohnert AS, Lagisetty PA. Policy pathways to address provider workforce barriers to buprenorphine treatment. Am J Prev Med. 2018;54:S230–S42.
   PubMed Web of Science ®Google Scholar
• Breen CT, Fiellin DA, Supply B. Access, and quality: where we have come and the path forward. J Law Med Ethics. 2018;46:272–78. doi:10.1177/1073110518782934.
   PubMed Web of Science ®Google Scholar
• Fornili KS, Fogger SA. Nurse practitioner prescriptive authority for buprenorphine: from DATA 2000 to CARA 2016. J Addict Nurs. 2017;28:43–48. doi:10.1097/JAN.0000000000000160.
   PubMed Web of Science ®Google Scholar
• Fiscella K, Wakeman SE, Beletsky L. Buprenorphine deregulation and mainstreaming treatment for opioid use disorder: X the X waiver. JAMA Psychiatry. 2019;76:229–30. doi:10.1001/jamapsychiatry.2018.3685.
   PubMed Web of Science ®Google Scholar
• Eisenberg JM, Power EJ. Transforming insurance coverage into quality health care: voltage drops from potential to delivered quality. Jama. 2000;284:2100–07. doi:10.1001/jama.284.16.2100.
   PubMed Web of Science ®Google Scholar
• Socías ME, Volkow N, Wood E. Adopting the ‘cascade of care’framework: an opportunity to close the implementation gap in addiction care? Addiction (Abingdon, England). 2016;111:2079. doi:10.1111/add.13479.
   PubMed Web of Science ®Google Scholar
• Williams A, Nunes E, Olfson M To battle the opioid overdose epidemic, deploy the ‘cascade of care’ model. 2017.
   Google Scholar
• Johnson KA, Williams AR, Chalk M. Health Affairs Blog [Internet]: health Affairs. 2018 October 23 [accessed 2019 Oct 08]. https://www.healthaffairs.org/do/10.1377/hblog20181018.540807/full/.
   Google Scholar
• Williams AR, Nunes EV, Bisaga A, Levin FR, Olfson M. Development of a Cascade of Care for responding to the opioid epidemic. Am J Drug Alcohol Abuse. 2019;45:1–10.
   PubMed Web of Science ®Google Scholar
• Prieto JT, McEwen D, Davidson AJ, Al-Tayyib A, Gawenus L, Sangareddy SRP, Blum J, Foldy S, Shlay JC. Monitoring opioid addiction and treatment: do you know if your population is engaged? Drug Alcohol Depend. 2019;202:56–60.
   PubMed Web of Science ®Google Scholar
• Yedinak JL, Goedel WC, Paull K, Lebeau R, Krieger MS, Thompson C, Buchanan AL, Coderre T, Boss R, Rich JD, et al. Defining a recovery-oriented cascade of care for opioid use disorder: A community-driven, statewide cross-sectional assessment. PLoS Med. 2019;16:e1002963–e.
   PubMed Web of Science ®Google Scholar
• Socías ME, Wood E, Kerr T, Nolan S, Hayashi K, Nosova E, Montaner J, Milloy M-J. Trends in engagement in the cascade of care for opioid use disorder, Vancouver, Canada, 2006–2016. Drug Alcohol Depend. 2018;189:90–95.
   PubMed Web of Science ®Google Scholar
• Barocas JA, White LF, Wang J, Walley AY, LaRochelle MR, Bernson D, Land T, Morgan JR, Samet JH, Linas BP, et al. Estimated prevalence of opioid use disorder in Massachusetts, 2011–2015: a capture–recapture analysis. Am J Public Health. 2018;108:1675–81.
   PubMed Web of Science ®Google Scholar
• Harris AH, Humphreys K, Bowe T, Tiet Q, Finney JW. Does meeting the HEDIS substance abuse treatment engagement criterion predict patient outcomes? J Behav Health Serv Res. 2010;37:25–39. doi:10.1007/s11414-008-9142-2.
   PubMed Web of Science ®Google Scholar
• Schmidt EM, Gupta S, Bowe T, Ellerbe LS, Phelps TE, Finney JW, Asch SM, Humphreys K, Trafton J, Vanneman M, et al. Predictive validity of a quality measure for intensive substance use disorder treatment. Subst Abuse. 2017;38:317–23.
   PubMed Web of Science ®Google Scholar
• Patient protection and affordable care Act. Sect. 18001 (2010).
   Google Scholar
• Foundation KF. Medicaid in the United States San Francisco. CA: Kaiser Family Foundation; 2019. https://files.kff.org/attachment/fact-sheet-medicaid-state-US.
   Google Scholar
• Foundation KF. Medicaid in Florida San Francisco. CA: Kaiser Family Foundation; 2019. accessed 2019 Oct. https://files.kff.org/attachment/fact-sheet-medicaid-state-FL.
   Google Scholar
• Wakeman SE, Larochelle MR, Ameli O, Chaisson CE, McPheeters JT, Crown WH, Azocar F, Sanghavi DM. Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Network Open. 2020;3:e1920622–e.
   PubMed Web of Science ®Google Scholar
• Sofuoglu M, DeVito EE, Carroll KM. Pharmacological and behavioral treatment of opioid use disorder. Psychiatric Res Clin Pract. 2019;1:4–15. doi:10.1176/appi.prcp.20180006.
   Google Scholar
• Forum NQ Behavioral health 2016–2018 final report. National Quality Forum; 2017 accessed 2017 Aug 28.
   Google Scholar
• Thomas CP, Garnick DW, Horgan CM, Miller K, Harris AH, Rosen MM. Establishing the feasibility of measuring performance in use of addiction pharmacotherapy. J Subst Abuse Treat. 2013;45:11–18.
   PubMed Web of Science ®Google Scholar
• Hser Y-I, Mooney LJ, Saxon AJ, Miotto K, Bell DS, Zhu Y, Liang D, Huang D. High mortality among patients with opioid use disorder in a large healthcare system. J Addict Med. 2017;11:315.
   PubMed Web of Science ®Google Scholar
• Bech AB, Clausen T, Waal H, JŠ B, Skeie I. Mortality and causes of death among patients with opioid use disorder receiving opioid agonist treatment: a national register study. BMC Health Serv Res. 2019;19:440. doi:10.1186/s12913-019-4282-z.
   PubMed Web of Science ®Google Scholar
• W Ha V, Jenness S, Brown CH, Wilensky U . Leveraging modularity during replication of high-fidelity models: lessons from replicating an agent-based model for HIV prevention. Unpublished paper. 2020.
   Google Scholar